» Articles » PMID: 17702869

Forerunner Genes Contiguous to RB1 Contribute to the Development of in Situ Neoplasia

Abstract

We used human bladder cancer as a model system and the whole-organ histologic and genetic mapping strategy to identify clonal genetic hits associated with growth advantage, tracking the evolution of bladder cancer from intraurothelial precursor lesions. Six putative chromosomal regions critical for clonal expansion of intraurothelial neoplasia and development of bladder cancer were identified by using this approach. Focusing on one of the regions, which includes the model tumor suppressor RB1, we performed allelotyping of single-nucleotide polymorphic sites and identified a 1.34-Mb segment around RB1 characterized by a loss of polymorphism associated with the initial expansion of in situ neoplasia. This segment contains several positional candidate genes referred to by us as forerunner genes that may contribute to such expansion. We subsequently concentrated our efforts on the two neighbor genes flanking RB1, namely ITM2B and CHC1L, as well as P2RY5, which is located inside RB1. Here, we report that ITM2B and P2RY5 modulated cell survival and were silenced by methylation or point mutations, respectively, and thus by functional loss may contribute to the growth advantage of neoplasia. We also show that homozygous inactivation of P2RY5 was antecedent to the loss of RB1 during tumor development, and that nucleotide substitutions in P2RY5 represent a cancer predisposing factor.

Citing Articles

Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.

Lee S, Bondaruk J, Wang Y, Chen H, Lee J, Majewski T Cell Rep. 2024; 43(5):114146.

PMID: 38676926 PMC: 11265536. DOI: 10.1016/j.celrep.2024.114146.


Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping.

Czerniak B, Lee S, Jung S, Kus P, Bondaruk J, Lee J Res Sq. 2024; .

PMID: 38659962 PMC: 11042420. DOI: 10.21203/rs.3.rs-3994376/v1.


The origin of bladder cancer from mucosal field effects.

Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y iScience. 2022; 25(7):104551.

PMID: 35747385 PMC: 9209726. DOI: 10.1016/j.isci.2022.104551.


Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.

Lokeshwar S, Lopez M, Sarcan S, Aguilar K, Morera D, Shaheen D Cancers (Basel). 2022; 14(11).

PMID: 35681556 PMC: 9179261. DOI: 10.3390/cancers14112578.


The role of the integral type II transmembrane protein BRI2 in health and disease.

Martins F, Santos I, da Cruz E Silva O, Tambaro S, Rebelo S Cell Mol Life Sci. 2021; 78(21-22):6807-6822.

PMID: 34480585 PMC: 11072861. DOI: 10.1007/s00018-021-03932-5.


References
1.
Ilyas M, Straub J, Tomlinson I, Bodmer W . Genetic pathways in colorectal and other cancers. Eur J Cancer. 1999; 35(3):335-51. DOI: 10.1016/s0959-8049(98)00431-6. View

2.
Oka K, Tomonaga Y, Nakazawa T, Ge H, Bengtsson U, Stanbridge E . Malignant transformation of human diploid fibroblasts and suppression of their anchorage independence by introduction of chromosome 13. Genes Chromosomes Cancer. 1999; 26(1):47-53. DOI: 10.1002/(sici)1098-2264(199909)26:1<47::aid-gcc7>3.0.co;2-8. View

3.
De La Vega F, Lazaruk K, Rhodes M, Wenz M . Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res. 2005; 573(1-2):111-35. DOI: 10.1016/j.mrfmmm.2005.01.008. View

4.
Tuziak T, Jeong J, Majewski T, Kim M, Steinberg J, Wang Z . High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest. 2005; 85(5):689-701. DOI: 10.1038/labinvest.3700270. View

5.
Kim M, Jeong J, Majewski T, Kram A, Yoon D, Zhang R . Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia. Lab Invest. 2006; 86(2):175-90. DOI: 10.1038/labinvest.3700378. View